• Pfizer’s latest pipeline update comes with a notice of three midnight program executions. The pharma giant has pruned three drugs from its substantial pipeline, according to the update. The most advanced is a Phase II diabetes program for PF-06291874; followed by the early stage cardio drug PF-06815345 (hyperlipidemia) as well as the neuro drug PF-06412562, also in Phase I. None of these were high profile projects, none of the terminations were explained.
• Astellas Pharma has licensed the AU-935 program, a therapy for eardrum perforations, from Auration Biotech.
• AbCheck s.r.o. says it achieved the first clinical milestone in its antibody discovery collaboration with Eli Lilly. The milestone, triggered by the commencement of patient enrollment for a Phase I study of an antibody discovered under the collaboration agreement, provides an undisclosed milestone payment from Lilly.
• BioClinica CEO John Hubbard was elected chairman of ACRO, an advocacy group for CROs and clinical services organizations around the world.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.Free Subscription